Anergic T cells are defective in both jun NH2-terminal kinase and mitogen-activated protein kinase signaling pathways by unknown
Anergic T  Cells  are Defective  in Both Jun NH2-terminal 
Kinase and Mitogen-activated  Protein Kinase 
Signaling Pathways 
By Dimuthu R. DeSilva,Wendi S. Feeser, Elizabeth  J.Tancula, 
and Peggy A. Scherle 
From the Dupont Merck Pharmaceutical Company, Inflammatory Diseases Research,  Wilmington, 
Delaware 19880-0400 
Summary 
T  helper type 1 cells (Thl) become anergic when stimulated through the antigen receptor in 
the absence of costimulation. They do not produce IL-2 or proliferate in response to subse- 
quent  stimulation.  Previous studies  have  indicated that  anergic  T  cells  are  defective in  the 
transactivational activity of the transcription factor, AP-1, which is required for optimal IL-2 
transcription. Using two murine Thl cell clones, we demonstrate that anergic Thl cells have 
defects in both jun NH2-terminal kinase (JNK) and extracellular signal-regulated kinase (ERK) 
activities. These kinases have been shown to be important for the upregulation of AP-1 activ- 
ity. Furthermore, our data show that ERK and JNK activities are restored when anergy is in- 
duced in the presence of the protein synthesis inhibitor cycloheximide, or when anergic T  cells 
are allowed to proliferate in response to exogenous IL-2. These treatments have previously 
been shown to prevent or reverse the anergic state. Our results suggest that defects in both JNK 
and ERK may result in the decreased AP-1  activity and the reduced IL-2 transcription  ob- 
served in anergic T  cells. 
I 
n  1987, Jenkins  and  Schwartz  showed  experimentally 
.that IL-2 and interferon-'y producing T  cells (Thl cells) 
require two signals from antigen-presenting cells (APC) 1 in 
order to produce these cytokines (1, reviewed in reference 
2). The first signal is provided by the TCR following occu- 
pancy by antigenic peptides bound to class II major histo- 
compatibility complex (MHC)  molecules. The second or 
"costimulatory" signal is known to be provided by B7-1 (3, 
4,  5)  and B7-2  (6,  7)  molecules on the  surface of APC. 
TCR occupancy in the absence of costimulation results  in 
suboptimal activation of T  cells,  with no IL-2 production 
and no resultant proliferation (1). In addition, such cells are 
also unresponsive (anergic) to subsequent stimulation with 
normal APC plus antigen (1). 
In response to antigen plus APC, anergized T  ceils have 
been shown to undergo early events characteristic of T  cell 
activation such as inositol phosphate production (8),  IL-2 
receptor (IL-2R) upregulation and increases in levels of in- 
tracellular calcium  (9).  Surface expression of TCR,  CD4 
(9),  and CD28  (D.R.  DeSilva and M.K. Jenkins,  unpub- 
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lished data)  are also not measurably altered. The major de- 
fect in anergic T cells seems to be a lack of accumulation of 
IL-2 mRNA  since anergic cells  proliferate in response to 
exogenously added IL-2 (9). In addition, T cell clones stim- 
ulated with antigen plus APC become anergized when treated 
with neutralizing antibodies to IL-2 (10). 
The series  of events culminating in IL-2 production by 
activated Thl cells is complex (11,  12,  13).  The IL-2 pro- 
moter contains an  enhancer region extending 300  nucle- 
otides 5' of the initiation site of transcription (14,  15). The 
transcription factors necessary for positive regulation of IL-2 
gene expression include the NF-AT/AP-1 complex, AP-1 
itself,  NFKB  and  octamer-binding  proteins.  All  of these 
factors are  either newly synthesized or posttranslationally 
modified subsequent to TCR occupancy. Alteration of any 
one of these binding sites results in a 60-90% decrease in 
the inducibility of the IL-2 gene. These factors alone, how- 
ever, do not result in maximal production of IL-2. A sec- 
ond stimulus, mediated by CD28 in complex with its ligand 
B7, activates yet another transcription factor, the CD28 re- 
ceptor  complex  (CD28RC).  Binding  of  CD28RC  to- 
gether with the transcription factors produced upon TCR 
occupancy results in maximal IL-2 production in Thl cells 
(16,  17, 18). 
Recent data have indicated that AP-1  transactivation is 
defective in anergic T  cells  (19) that correlates with a lack 
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composed of Fos and Jun  family members.  During T  cell 
activation, Fos and Jun levels increase and the Jun proteins 
become phosphorylated, increasing their ability to transac- 
tivate (20).  Two  major kinase pathways have  been impli- 
cated in the upregulation of AP-1 activity during the T  cell 
response to antigen. The first is the mitogen-activated pro- 
tein kinase (MAPK) pathway that is downstream ofp21ras 
(21). Ras, when it is in the GTP-bound state, localizes the 
serine/threonine  kinase R.af to  the  membrane  where  it is 
phosphorylated and activated. P,  af can then phosphorylate 
and  stimulate  the  dual-specific kinase  MEK,  which  acti- 
vates extracellular signal-regulated kinase  (ERK)  by direct 
phosphorylation on threonine  and  tyrosine residues. ERK 
phosphorylates  and  increases the  activity of a  number  of 
proteins including elk-l, a  transcription factor involved in 
the upregulation of the c-fos gene. The second pathway in- 
volved in AP-1 upregulation is the c-jun NH2-terminal ki- 
nase  (JNK)  pathway. Although the upstream components 
of this pathway are not as clearly defined, it is thought that 
the  serine/threonine  kinase  MEKK1  phosphorylates  and 
stimulates  the  dual  specificity  kinase  MKK4/SEK1  that 
phosphorylates the MAPK family member, JNK  (20,  22). 
ActivatedJNK can then phosphorylate c-jun on two NHe- 
terminal  serine  residues  (Ser63  and  Set73)  critical for  its 
transactivational activity. 
The  lack  of AP-1  transactivation  observed  in  anergic 
cells could  therefore  be  due  to  impaired signaling in  the 
pathways leading to  los  and jun  upregulation  and  activa- 
tion.  In this report, we examined the levels of ERK2  and 
JNK activation in control vs.  anergic T  cells after stimula- 
tion  through  the  TCR..  We  demonstrate  that  both  ERK 
and JNK activities are reduced in anergic cells. These data 
suggest that defects in the MAPK and JNK pathways may 
be responsible for the decreased AP-1  activity and the re- 
duced IL-2 transcription observed in anergic T  cells. 
Materials and Methods 
Mice 
B10.BR/SgSn mice were purchased from the Jackson Labora- 
tory  (Bar  Harbor,  ME).  BALB/c  mice  were  purchased  from 
Charles River (Raleigh, NC).  Single-cell suspensions of whole 
spleen obtained from these mice were used as APC for mainte- 
nance of Thl clones and in proliferation assays. 
T  Cell Clones 
A.E7.  This  is  a  Bl0.A-derived CD4+8 -,  CD28 +murine 
Thl clone (23) that expresses a V~3/Vcill TCFZ. A.E7 cells pro- 
duce IL-2, 1L-3, and IFN-y upon stimulation with the COOH- 
terminal cyanogen bromide fragment (residues 81-104) of  pigeon 
cytochrome  c or a  synthetic peptide based on  the  moth  cyto- 
chrome c sequence (called DASP)  (24) bound to I-E  k molecules 
on the surface of APC. The DASP peptide was synthesized using 
the  Merrifield method  at  the  University of Minnesota  Micro- 
chemical facility. 
ThI7.  This  murine  Thl  clone  was  derived from BALB/c 
mice immunized s.c. with the influenza virus A/PR/8/34 (PR8) 
as described (25).  It is CD4+8 -, CD28 + and produces IL-2 and 
IFN-~/upon stimulation with the hemagglutinm (HA) molecule 
of influenza virus PtL8. The viral antigen was in the form of al- 
lantoic fluid from virus-infected embryonated hen eggs. Virus ti- 
ters were  determined by agglutination of chicken  erythrocytes 
and are expressed as hemagglutinating units (HAU) (25). 
Both A.E7 and Th17  cells were maintained in 24-well plates 
on a "rest-stimulation" protocol (23)  using mitomycin-c treated 
APC, antigen and recombinant human IL-2 (Boehringer Mann- 
helm, Indianapolis, IN). Cells used in experiments were rested at 
least 5 d after addition oflL-2 and were separated from debris and 
dead APC  by  histopaque  1077  (Sigma Chem.  Co.,  St.  Louis, 
MO) density gradient centrifugation. 
Anergy Induction 
During the preculture, A.E7 or Th17 T  cells (1-3 ￿  10S/well 
or 2-10 ￿  106/plate)  were incubated in 24-well plates or 10-cm 
Falcon 3003 petri plates coated with 10 lxg/ml purified anti-CD3 
mAb (clone 145-2Cll; 26) as previously described (27).  In some 
experiments, 0.1 I~g/ml cycloheximide was added to cells to pre- 
vent induction of anergy (28).  T  cells were  removed from the 
immobilized anti-CD3 after 1-2 days and transferred into fresh 
wells where they were allowed to rest in medium alone for 2 d. 
To reverse the anergic state, anergic T cells from some experi- 
ments were  removed from immobilized anti-CD3  after  1-2  d, 
washed and cultured for 7 d in the presence of 30 U/ml recombi- 
nant human  IL-2. After culture in IL-2, cells were washed and 
rested for 2-5 d in medium alone before stimulation. 
After the rest period, Thl  cells were  treated with  anti-CD3 
plus anti-CD28 (2 p,g/ml each) cross-linked with 2.0 p,g/mI goat 
anti-hamster IgG (Cappel Research Products, Durham,  NC)  or 
PMA plus ionomycin (100  ng/ml and 1.0  p,M,  respectively) for 
activation before performing various assays for detecting differ- 
ences between control resting T cells and anergic T cells. 
Cellular Extracts 
Total cellular extracts were made from A.E7 or Th17  T  cells 
(3-15 ￿  106 cells/treatment) which were unstimulated, or stimu- 
lated for  15  min at 37~  with  either anti-CD3 plus anti-CD28 
antibodies or PMA plus ionomycin. These extracts were used in 
Western blots, ERK KINASE assays, andJNK assays. After the 15 
rain incubation, T cells were pelleted and washed twice with cold 
PBS. The cells were then lysed in 100 ~1 of cold lysis buffer con- 
sisting of 10 mM Ttis (pH 7.2), 150 mM NaC1, 1.0% Triton X-100, 
1.0% sodium deoxycholate, and 0.1% SDS to which protease in- 
hibitors and phosphatase inhibitors had been freshly added. After a 
10-min incubation on ice, the extracts were spun for 15 rain at 
14,000 rpm in Eppendorftubes at 4~  to pellet cellular debris. The 
superuatant was removed and protein concentrations determined 
using the Bio Rad protein assay (Bio Rad Labs., Hercules, CA). 
Western Blots 
Cellular extracts from A.E7 or Th17  T  cells  (10-20/~g pro- 
rein/lane) were run on a  10% SDS-polyacrylamide  gel following 
denaturation by boiling for 5 min in SDS loading buffer. Following 
electrophoresis, proteins were transferred onto Hybond-ECL ni- 
trocellulose membranes (Amersham Life Science Inc., Arlington 
Heights, IL) and probed with the primary antibody (Raf-1; Santa 
Cruz Biotechnology, Inc., Santa Cruz, CA) followed by a perox- 
idase-conjugated secondary antibody,  and  detected  using ECL 
Western  blotting detection  reagents  (Amersham  Life  Sciences, 
Buckinghamshire,  England).  Blots were  exposed to  autoradio- 
graphic film (Du Pont & Co., Wilmington, DE) for 1-2 min for 
detection. 
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Cellular extracts from A.E7 or Th17 T  cells (25-50 p~g protein 
diluted 1:10 in water for a final concentration of  0.1% Triton X-100) 
were incubated for 3 h at 4~  with 10 ng GST-c-jun (29) bound 
to  agarose  beads.  During  this  incubation, JNK  in  the  extracts 
binds c-jun. The beads were then washed three times in cold lysis 
buffer consisting of Tris-buffered sahne containing 0.1% Triton 
X-100 and protease inhibitors. The beads were pelleted and re- 
suspended in 25  ~1  of kinase buffer containing 20  mM  Hepes 
(pH 7.0), 5 mM 2-ME, 10 mM MgC12, 0.1 mg/ml BSA, 10 ~M 
unlabeled ATP and 10 ~Ci [33p]~/ATP. The reaction mix was in- 
cubated at 37~  for 20 rain, and washed three times in cold lysis 
buffer.  The  beads were  resuspended in SDS  loading buffer and 
boiled for 5 rain to extract bound proteins. The beads were pel- 
leted  and the  proteins  run  on  a  10%  SDS-polyacrylamide gel. 
The gel was dried and exposed to a Phosphorlmager screen over- 
night after  which  quantitation was  performed  using the  Image 
Quant. program (Molecular Dynamics, Sunnyvale, CA). 
Kinase Assays for ERK Activity 
Cellular extracts from A.E7 or Thl7 T  cells (100--300 p,g protein) 
were brought up to 0.5 ml with PBS containing protease inhibi- 
tots and rocked for 1 h  at 4~  with 1.0 ~g ofERK2 mAb (Santa 
Cruz Biotechnology Inc.). A 50-bd slurry of protein A-agarose was 
then added to  each tube and the tubes incubated for  1 h  at 4~ 
with rocking. The tubes were centrifuged at 8,000 rpm for 5 min 
at 4~  and washed three times with PBS containing protease in- 
hibitors. The pellets were  then washed  once with kinase buffer 
(see JNK assay),  and resuspended in 25  p~l of kinase buffer con- 
taining 10 p~Ci [33p]~/ATP and 2.5 Ixg myelin basic protein (MBP; 
Upstate Biotechnology Inc., Lake Placid, NY). The tubes were then 
incubated for 20 min at 30~  Samples were resuspended in SDS 
loading buffer and boiled for 5 latin to extract bound proteins. The 
tubes were  centrifuged and the  supematent was  run on a  14% 
SDS-polyacrylamide  gel.  The  gel  was  dried  and  exposed  to  a 
Phosphorlmager  screen overnight after which  quantitation was 
performed using the Image Quant. program (Molecular Dynamics). 
Results 
JNK Activity Is Abrogated in Anergic T Cells.  Anergic  Thl 
cells have been reported  to  show  decreased  AP-1  binding 
compared  to  control T  cells  3  h  after  stimulation,  a  time 
point preceding peak transcription oflL-2 (19). This could be 
due to defects in the signal transduction cascades leading to 
the upregulation and/or posttranslational modification of the 
AP-1 subunits, los andjun. We therefore decided to exam- 
ine anergic T  cells for their ability to  phosphorylate  c-jun 
since  it has been shown  that  transactivation by jun  is  de- 
pendent on its phosphorylation state  (20).  T  cells were an- 
ergized by pretreatment with immobilized anti-CD3 in the 
absence of APC.  The cells were  rested for 2-3  d  and then 
stimulated with  anti-CD3  plus  anti-CD28  or with  PMA 
plus ionomycin. Cells anergized in this way failed to prohf- 
erate upon restimulation with antigen and failed to produce 
IL-2  although  they proliferated  in response  to  exogenous 
IL-2 (data not shown). 
Cell  lysates  from  anergic  A.E7  T  cells  were  compared 
with extracts from control T  cells for their ability to phos- 
phorylate the  NH 2 terminus of recombinant human c-jun 
protein.  As  shown  in  Fig.  1,  unstimulated  T  cells  (both 
control and anergic) showed  a  basal, low level ofJNK  ac- 
Figure  1.  JNK activity is defective in anergic T  cells. The ability of 
JNK from cellular extracts of control or anergic A.E7 T cells to phospho- 
rylate  a  recombinant c-jun protein  was  tested.  The  band  represents 
[33P]~/ATP incorporated  into phosphorylated c-jun. Lanes I-3 represent 
control cells and lanes 4-6 represent anergic cells. Cells were either un- 
stimulated  (lanes 1 and 4), stimulated with cross-linked anti-CD3 plus 
anti-CD28 (lanes 2 and 5) or stimulated with PMA plus ionomycin (lanes 
3 and 6). Quantitation  of the increase in kinase activity was performed us- 
ing the Image Quant. program. 
Figure 2.  JNK activity is restored when T cells are made anergic in the 
presence of CHX or when anergic T cells are allowed to undergo prolif- 
eration.  The ability of JNK from cellular extracts of control or anergic 
Th17 T  cells to phosphorylate  a recombinant c-jun protein was tested. 
The band represents [33p]~/ATP  incorporated  into pbosphorylated c-jun. 
Lanes 1 and 2 represent control cells; lanes 3 and 4 represent anergic cells; 
lanes 5 and 6 represent cells anergized in the presence of CHX and lanes 7 
and 8 represent anergic cells allowed to undergo proliferation in the pres- 
ence of exogenously added IL-2 (these cells were a subset of the anergic 
ceils shown in lanes 3 and 4). Odd numbers represent lanes in which cells 
were unstimulated, and even numbers represent lanes in which cells were 
stimulated with PMA plus ionomycin. Quantitation of the increase in ki- 
nase activity was performed using the Image Quant. program. 
2019  DeSilva et al. tivity. JNK  activity in  control T  cells  increased  following 
anti-CD3 plus anti-CD28 stimulation (lane 2) and was dra- 
matically increased during PMA plus ionomycin treatment 
(lane 3).  In contrast, JNK activity did not increase in aner- 
gic T  cells stimulated with either anti-CD3 plus anti-CD28 
(compare  lane  5  with  lane  2)  or  PMA  plus  ionomycin 
(compare  lane  6  with  lane  3).  Identical  results  have  been 
obtained using another Thl  clone, Th17 (Fig. 2). 
Figure 3.  ER_K  KINASE  activity  is defective in anerglc T cells and is re- 
stored when anergy is induced in the presence ofCHX. (A) The ability of 
ERK from cellular extracts of  control or anergic A.E7 T cells to phosphor- 
ylate MBP was tested. The band represents [33P]~/ATP  incorporated into 
phosphorylated  MBP. Lanes I-3 represent control cells and lanes 4-6 rep- 
resent anergic cells. Cells were either unstimulated (lanes 1 and 4), stimu- 
lated with cross-linked anti-CD3 plus anti-CD28 (lanes 2 and 5) or stim- 
ulated with  PMA plus ionomycin (lanes 3  and  6).  Quantitation was 
performed using the Image Quant. program. (B) The ability of  ERK from 
cellular extracts of  control or auergic Th17 T cells to phosphorylate  MBP 
was tested. The band represents [33P]'yATP  incorporated iuto phosphory- 
lated MBP. Lanes 1 and 2 represent control ceils; lanes 3 and 4 represent 
anergic cells; and lanes 5 and 6 represent cells anergized in the presence of 
CHX.  Odd numbers represent lanes in which cells were unstimulated, 
and even numbers represent lanes in whicb cells were stimulated with 
PMA plus ionomycin. Quantitation of the increase in kinase activity was 
performed using the Image Quant. program. 
Activation of  JNK was restored by including the protein 
synthesis inhibitor cycloheximide (CHX) during the induc- 
tion ofanergy (Fig. 2, compare lane 6 with lane 4), or when 
anergic Thl cells were allowed to undergo proliferation in re- 
sponse to exogenous IL-2 (Fig. 2, compare lane 8 with lane 
4).  Therefore, our data indicate that JNK activity is restored 
by treatments that are known to prevent (CHX) or reverse 
(IL-2) the anergic phenotype, suggesting that defective JNK 
is responsible for maintaining the anergic phenotype. The lack 
of  JNK activity observed in anergic cells was not due to a shift 
in the  kinetics  of the  response.  A  time  course experiment 
indicated that JNK activity in control resting T  cells peaked 
at  20  rain  and  was  at  background levels  by 60  rain  post- 
stimulation. JNK activity remained at background levels at 
all time points tested in anergic T  cells (data not shown). 
ERK Activity Is Defective in Anergic T  Cells.  To  study  the 
other  major  signal  transduction  pathway  downstream  of 
TCR. ligation and preceding AP-1 binding at the IL-2 en- 
hancer,  we examined EP,  K2 activity in anergic  or control 
T  cells.  As  shown  in  Fig.  3  A,  EtkK  activity increased  in 
control T  cells  stimulated  with  either anti-CD3  plus  anti- 
CD28 or PMA plus ionomycin as measured by phosphory- 
lation of  MBP. In contrast, no increase in ERK activity was 
observed after stimulation  of anergic cells  (Fig.  3 A,  com- 
pare lane  6 with lane 3).  Similar to the results observed for 
JNK activity, the presence of cycloheximide during anergy 
induction prevented  the loss  of ERK activity observed  in 
anergic  T  cells  (Fig.  3  B,  compare lane  6  to  lane  4).  Fur- 
ther, proliferation of anergic T  cells  in the presence of IL-2 
restored  the ability of ERK to become activated upon  re- 
stimulation  (data not shown). 
Phosphorylation  of Raf Is  Not  Defective  in Anergic  T  Cells. 
To determine ifkinase function was generally suppressed in 
anergic cells, we examined the phosphorylation state ofgaf-1, 
an upstream kinase in the MAPK pathway. The unphosphor- 
ylated and phosphorylated forms of Raf can be distinguished 
because phosphorylation of  Rafresults in its decreased mobil- 
ity on SDS-PAGE. As shown in Fig. 4, the phosphorylated 
form of  Rafwas seen in both control and anergic T  cells after 
stimulation with  PMA plus ionomycin. Thus,  anergy does 
not prevent  the  increased  phosphorylation  of Raf associ- 
ated with T  cell activation.  The kinase activity of Raf-1  in 
anergic cells, however, was lower than that seen in control 
T  cells.  Control cells  increased their kinase activity two- to 
threefold  during  stimulation  with  PMA  and  ionomycin, 
and this increase is absent in anergic T  cells (data not shown). 
Discussion 
The primary deficiency in anergic Thl  cells appears to be 
their inability to produce IL-2. Anergic T  cells possess  com- 
parable  levels of both TCI:k (9)  and CD28  (D.tL.  DeSilva 
and M.K. Jenkins,  unpublished data) on their surface com- 
pared to control resting cells. However, several factors down- 
stream  of TCR  and  CD28  occupancy have  been  impli- 
cated in causing an IL-2 production deficiency in anergic T 
cells.  Studies  have indicated  decreased p56  kk levels and in- 
creased  p59#n  levels  (30),  altered  tyrosine phosphorylation 
2020  Anergic Th 1 Cells Possess Defects in Protein Kinases Figure  4.  Raf phosphorylation  is  not  defective in  anergic T  cells. 
Western blots of control or anergic T cells which were unstimulated or 
stimulated with PMA plus ionomycin were probed with an antibody to 
Raf-1, followed by a peroxidase-conjugated goat anti-rabbit antibody as 
the second step. A slower migrating band represents the phosphorylated 
form of Raf, and the faster migrating band is the unphosphorylated form 
of Raf. Lanes 1 and 2 represent control cells and lanes 3 and 4 represent 
anergic cells. Cells were either unstimulated (lanes 1 and 3) or stimulated 
with PMA plus ionomycin (lanes 2 and 4). Quantitation of the percent- 
age of Raf-1 in the unphosphorylated and phosphorylated states was per- 
formed using the Image Quant. program. 
(31),  and  decreased AP-1  transactivation  (19)  in  anergic  T 
cells.  Our  data  have  indicated  that  anergic  Thl  cells  also 
have  reduced  levels  of JNK  and  ERK  activity  during  re- 
stimulation.  This finding suggests that both fos andjun sub- 
units of the transcription factor AP-1 will be affected in an- 
ergic T  cells. Jun activity may be reduced  due to its lack of 
phosphorylation  by JNK  and  Fos levels  may be  decreased 
due to the lack ofERK  phosphorylation of Elk-l, a known 
regulator  of Fos  transcription.  Together,  these  effects may 
result  in  the  decreased  levels  of AP-1  activity  in  anergic 
cells  reported  by other  researchers  (19,  D.R.  DeSilva  and 
M.K. Jenkins,  unpublished  data). 
Ras  and  Raf-1  activities  are  known  to  be  required  for 
the  stimulation  of IL-2  promoter  activity  in  T  cells  (32, 
33).  A  recent report has also indicated  that stimulating  the 
ERK pathway by expressing active MEK-1  enhanced  IL-2 
promoter  and  NF-AT-driven  transcription  in  a  manner 
identical to expressing active Raf-1, whereas inhibiting ERK 
activity by expressing interfering mutants  of MEK-1  or by 
expressing the ERK-specific phosphatase, MKP-1  decreased 
IL-2  promoter  activity  (34).  These  authors  conclude  that 
MEK-1  and  ERKs function  in  conveying stimulatory  sig- 
nals  from Raf-1  to the  IL-2 gene.  This  data is compelling 
evidence  that ERK  is a  required  kinase in IL-2 gene tran- 
scription,  and that a defect in its kinase ability could lead to 
the paralysis in IL-2 production seen in anergic T  cells. 
The defects inJNK  and ERK activity were overcome by 
the  presence  of cycloheximide  during  anergy induction  or 
by  allowing  anergic  T  cells  to  undergo  several  rounds  of 
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cell division in response to exogenous  IL-2. Previous stud- 
ies  have  shown  that  anerg'y  could  not  be  induced  in  the 
presence  of cycloheximide  (28),  and that anergic Thl  cells 
reverse their anergic phenotype following proliferation  (10, 
35).  Kang  et  al.  (19)  also  observed  that  anergic  Thl  cells 
that proliferated in response to exogenously added IL-2 no 
longer  showed  decreased  AP-1  binding.  In  combination, 
these results suggest that components of AP-1  may be reg- 
ulated by a factor that is newly synthesized  in cells receiv- 
ing TCR  signals in the absence of cell division and that this 
factor is lost if proliferation occurs.  Our results suggest that 
this  factor acts to  suppress JNK  and  ERK  activation.  This 
may occur by  (a)  preventing  the  synthesis  or activation  of 
JNK and ERK  or  (b) enhancing  the  degradation  or inacti- 
vation of  JNK and ERK in anergic T  cells. 
Although  we have demonstrated  that Raf is phosphory- 
lated normally in anergic  cells,  the kinase activity of Raf-1 
in anergic cells was lower than that seen in control T  cells. 
Control  cells increased  their kinase activity two-  to three- 
fold during stimulation with PMA and ionomycin,  and this 
increase is absent in anergic T  cells (data not shown).  Previ- 
ous studies have demonstrated  that the activity of Raf does 
not  correlate  with  its  level  of phosphorylation  (36).  The 
finding  that  Raf activity  is  also  decreased  in  anergic  cells 
suggests  that  there  is  a  defect  in  the  activation  of an  up- 
stream component  common  to both JNK  and ERK  path- 
ways, such as Ras  (29, 37).  Recent  data from Frank Fitch's 
laboratory  has  indicated  that  Ras  activation  is blocked  in 
anergic Thl  clones (38). Downstream of Ras, these authors 
found that anergic Thl  cells were defective in TCR-medi- 
ated  MAP-2  kinase  activation.  These results  are  consistent 
with our data. However, these authors found no alterations 
in  the  inductive  tyrosine  phosphorylation  of the  guanine 
nucleotide-releasing  factor, Vav, or in that of Shc. Also, as- 
sociation  of Grb-2  with  Shc  after  TCR  stimulation  was 
seen  to  be  comparable  in  control  and  anergic  cells.  They 
also found  no significant differences in levels of rasGAP in 
anergic  cells.  These  data  suggest  that  the  early  signaling 
events  are intact in anergic  cells.  In addition  to  a  defect in 
Ras,  there  may  also  be  simultaneous  effects  on  upstream 
components  unique  to  each  pathway,  such  as Rac  and/or 
Rho family members in the case of  JNK (39, 40)  or on the 
individual MEK family members.  Finally, it is also possible 
that anergic T  cells have higher levels ofphosphatases which 
result in rapid inactivation of several kinases within these cells. 
T  cell clonal anergy may be an important mechanism for 
peripheral tolerance.  In vivo models for donal anergy exist, 
although  the  true  incidence  of clonal  anergy in  self toler- 
ance is not yet known.  There are many examples for aner- 
gic T  cells being present in the periphery  (41,  42,  43,  44). 
Blackman  et al.  (45)  have shown  that tolerance  to the  su- 
perantigen  Mls-1 a in  mice  transgenic  for a Vj88.1  TCR  is 
maintained by both clonal deletion and anergy.  It is plausi- 
ble,  therefore,  that  anergic  T  cells  may  possess  defects  in 
more than one key signaling event leading to IL-2 produc- 
tion, since loss of the anergic phenotype could result in au- 
toimmunity and tissue destruction,  serious consequences  to 
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